EMA’s PRIME Sees New Targets, More Approvals But Few Fast-Track Reviews

 
• By Neena Brizmohun
Advanced therapies continue to dominate the types of substances entering the PRIME scheme • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards